Clinical trials · Michigan
Metastatic Breast Cancer clinical trials in Michigan
We’re tracking 103 recruiting metastatic breast cancer studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Detroit, MichiganAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Grand Rapids, MichiganAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Detroit, MichiganAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Farmington Hills, MichiganAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Sterling Heights, MichiganAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
Ann Arbor, MichiganAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Detroit, MichiganAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Detroit, MichiganAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Detroit, MichiganAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Ann Arbor, MichiganAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Lansing, MichiganAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Detroit, MichiganAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Detroit, MichiganAges 18 years+ - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Brighton, MichiganAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Sterling Heights, MichiganAges 18 years+ - NCT05430009RecruitingPhase 1
Radiation to liver plus immunotherapy for metastatic lung cancer
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
Ann Arbor, MichiganAges 18 years+
Metastatic Breast Cancer trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting metastatic breast cancer studies listed above.
- Barbara Ann Karmanos Cancer Institute · 5 studies
- START Midwest · 4 studies
- Profound Research LLC · 3 studies
- University of Michigan · 3 studies
- Wayne State University/Karmanos Cancer Institute · 3 studies
- BAMF Health · 2 studies
- Cancer & Hematology Centers of Western Michigan · 2 studies
- Corewell Health William Beaumont University Hospital · 2 studies
What taking part in a metastatic breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Breast Cancer trials in other states
Common questions
- Are there metastatic breast cancer clinical trials in Michigan?
- Yes. We're currently tracking 103 recruiting metastatic breast cancer studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast cancer study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast cancer studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.